Advertisement

Ads Placeholder
Loading...

SI-BONE, Inc.

SIBNNASDAQ
Healthcare
Medical - Devices
$13.12
$0.11(0.85%)
U.S. Market opens in 19h 1m

SI-BONE, Inc. Fundamental Analysis

SI-BONE, Inc. (SIBN) shows moderate financial fundamentals with a PE ratio of -30.19, profit margin of -9.41%, and ROE of -11.00%. The company generates $0.2B in annual revenue with strong year-over-year growth of 20.37%.

Key Strengths

Cash Position25.90%
PEG Ratio-2.20
Current Ratio8.55

Areas of Concern

ROE-11.00%
Operating Margin-11.11%
We analyze SIBN's fundamental strength across five key dimensions.

The stock receives a Fundamental Health Score of 31.6/100 based on profitability, valuation, growth, and balance sheet metrics. The F grade reflects weak fundamentals and significant financial concerns.

Fundamental Health Score

F
31.6/100

We analyze SIBN's fundamental strength across five key dimensions:

Efficiency Score

Weak

SIBN struggles to generate sufficient returns from assets.

ROA > 10%
-7.93%

Valuation Score

Excellent

SIBN trades at attractive valuation levels.

PE < 25
-30.19
PEG Ratio < 2
-2.20

Growth Score

Excellent

SIBN delivers strong and consistent growth momentum.

Revenue Growth > 5%
20.37%
EPS Growth > 10%
33.63%

Financial Health Score

Excellent

SIBN maintains a strong and stable balance sheet.

Debt/Equity < 1
0.01
Current Ratio > 1
8.55

Profitability Score

Weak

SIBN struggles to sustain strong margins.

ROE > 15%
-1100.48%
Net Margin ≥ 15%
-9.41%
Positive Free Cash Flow
No

Key Financial Metrics

Is SIBN Expensive or Cheap?

P/E Ratio

SIBN trades at -30.19 times earnings. This suggests potential undervaluation.

-30.19

PEG Ratio

When adjusting for growth, SIBN's PEG of -2.20 indicates potential undervaluation.

-2.20

Price to Book

The market values SI-BONE, Inc. at 3.22 times its book value. This suggests the stock is fully valued or overvalued on an asset basis.

3.22

EV/EBITDA

Enterprise value stands at -73.30 times EBITDA. This is generally considered low.

-73.30

How Well Does SIBN Make Money?

Net Profit Margin

For every $100 in sales, SI-BONE, Inc. keeps $-9.41 as profit after all expenses.

-9.41%

Operating Margin

Core operations generate -11.11 in profit for every $100 in revenue, before interest and taxes.

-11.11%

ROE

Management delivers $-11.00 in profit for every $100 of shareholder equity.

-11.00%

ROA

SI-BONE, Inc. generates $-7.93 in profit for every $100 in assets, demonstrating efficient asset deployment.

-7.93%

Following the Money - Real Cash Generation

Operating Cash Flow

SI-BONE, Inc. generates limited operating cash flow of $-685.20K, signaling weaker underlying cash strength.

$-685.20K

Free Cash Flow

SI-BONE, Inc. generates weak or negative free cash flow of $-9.23M, restricting financial flexibility.

$-9.23M

FCF Per Share

Each share generates $-0.21 in free cash annually.

$-0.21

FCF Yield

SIBN converts -1.57% of its market value into free cash.

-1.57%

Financial Ratios Analysis

Valuation Ratios

P/E Ratio

Price to earnings ratio

-30.19

vs 25 benchmark

PEG Ratio

Price/earnings to growth ratio

-2.20

vs 25 benchmark

P/B Ratio

Price to book value ratio

3.22

vs 25 benchmark

P/S Ratio

Price to sales ratio

2.88

vs 25 benchmark

Financial Health

Debt/Equity

Total debt to shareholders' equity

0.006

vs 25 benchmark

Current Ratio

Current assets to current liabilities

8.55

vs 25 benchmark

Efficiency Ratios

ROE

Return on equity percentage

-0.11

vs 25 benchmark

ROA

Return on assets percentage

-0.08

vs 25 benchmark

ROCE

Return on capital employed

-0.10

vs 25 benchmark

How SIBN Stacks Against Its Sector Peers

MetricSIBN ValueSector AveragePerformance
P/E Ratio-30.1928.45 Better (Cheaper)
ROE-11.00%763.00% Weak
Net Margin-9.41%-45265.00% (disorted) Weak
Debt/Equity0.010.34 Strong (Low Leverage)
Current Ratio8.552795.60 Strong Liquidity
ROA-7.93%-16588.00% (disorted) Weak

SIBN outperforms its industry in 3 out of 6 key metrics, but lagging in ROE.

Historical Growth Performance

5-Year Growth Trajectory

This section reviews SI-BONE, Inc.'s 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.

Revenue CAGR

48.00%

Industry Style: Defensive, Growth, Innovation

High Growth

EPS CAGR

52.04%

Industry Style: Defensive, Growth, Innovation

High Growth

FCF CAGR

76.59%

Industry Style: Defensive, Growth, Innovation

High Growth

Fundamental Analysis FAQ